Identification of serum proteome components associated with progression of non-small cell lung cancer.

Monika Pietrowska; Karol Jelonek; Malwina Michalak; Małgorzata Roś; Paweł Rodziewicz; Klaudia Chmielewska; Krzysztof Polański; Joanna Polańska; Agnieszka Gdowicz-Kłosok; Monika Giglok; Rafał Suwiński; Rafał Tarnawski; Rafał Dziadziuszko; Witold Rzyman; Piotr Widłak

doi:10.18388/abp.2014_1903

Monika Pietrowska Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Karol Jelonek Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland and Polish-Japanese Institute of Information Technology, Bytom, Poland.;
Malwina Michalak Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Małgorzata Roś Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland and Polish-Japanese Institute of Information Technology, Bytom, Poland.;
Paweł Rodziewicz Polish Academy of Science, Institute of Bioorganic Chemistry, Poznań, Poland.;
Klaudia Chmielewska Polish Academy of Science, Institute of Bioorganic Chemistry, Poznań, Poland.;
Krzysztof Polański Silesian University of Technology, Gliwice, Poland.;
Joanna Polańska Silesian University of Technology, Gliwice, Poland.;
Agnieszka Gdowicz-Kłosok Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Monika Giglok Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Rafał Suwiński Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Rafał Tarnawski Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;
Rafał Dziadziuszko Medical University of Gdańsk, Gdańsk, Poland.;
Witold Rzyman Medical University of Gdańsk, Gdańsk, Poland.;
Piotr Widłak Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.;

DOI: https://doi.org/10.18388/abp.2014_1903

Abstract

The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.